Literature DB >> 15486392

A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis.

Michael H Baumann1, B Wayne McAlpin, Keith Brown, Praful Patel, Imtiaz Ahmad, Robert Stewart, Marcy Petrini.   

Abstract

STUDY
PURPOSE: Train-of-four (TOF) monitoring is often recommended during the continuous use of neuromuscular blockade (NMB) [paralysis] in the ICU. Prior study results are conflicting regarding the benefits of TOF monitoring.
DESIGN: Thirty patients in the medical ICU were randomized to TOF monitoring (n = 16) or to clinical assessment (n = 14) during continuous cisatracurium infusion. TOF monitoring was done at least every 4 h, with the goal being maintenance of one to two twitches. Statistical analysis was performed by two-tailed, unpaired t test (with Bonferroni correction for multiple comparisons), chi(2), and Fisher exact test, with p < 0.05 considered significant. Given a power of 80%, and the variance seen in the two groups, we estimate that the sample size used is sufficient to detect a change of > or = 60 min between groups for recovery time.
RESULTS: The mean recovery time after cessation of paralytics was no different between TOF and clinical assessment (45 +/- 7 min vs 38 +/- 10 min, respectively [mean +/- SEM]). No differences were noted for mean APACHE (acute physiology and chronic health evaluation) II entry scores, glomerular filtration rates, or use of corticosteroids. No significant differences were noted between TOF monitoring and clinical assessment in mean total paralysis time (4,118 +/- 1,012 min vs 3,188 +/- 705 min, respectively), mean total cisatracurium dose (920 +/- 325 mg vs 715 +/- 167 mg), or dosage (2.3 +/- 0.2 microg/kg/min vs 2.9 +/- 0.2 microg/kg/min).
CONCLUSIONS: TOF monitoring does not lead to improved recovery time or lower cisatracurium dosing compared with monitoring by clinical assessment. We conclude that TOF monitoring is unnecessary, and careful titration of the neuromuscular blocking agent by clinical assessment alone is sufficient in patients undergoing continuous cisatracurium NMB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486392     DOI: 10.1378/chest.126.4.1267

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Management of mechanical ventilation in acute severe asthma: practical aspects.

Authors:  Mauro Oddo; François Feihl; Marie-Denise Schaller; Claude Perret
Journal:  Intensive Care Med       Date:  2006-01-27       Impact factor: 17.440

2.  Design and Rationale of the Reevaluation of Systemic Early Neuromuscular Blockade Trial for Acute Respiratory Distress Syndrome.

Authors:  David T Huang; Derek C Angus; Marc Moss; B Taylor Thompson; Niall D Ferguson; Adit Ginde; Michelle Ng Gong; Stephanie Gundel; Douglas L Hayden; R Duncan Hite; Peter C Hou; Catherine L Hough; Theodore J Iwashyna; Kathleen D Liu; Daniel S Talmor; Donald M Yealy
Journal:  Ann Am Thorac Soc       Date:  2017-01

3.  How to reduce cisatracurium consumption in ARDS patients: the TOF-ARDS study.

Authors:  Sami Hraiech; Jean-Marie Forel; Christophe Guervilly; Romain Rambaud; Samuel Lehingue; Mélanie Adda; Pierre Sylla; Sabine Valera; Julien Carvelli; Marc Gainnier; Laurent Papazian; Jérémy Bourenne
Journal:  Ann Intensive Care       Date:  2017-08-02       Impact factor: 6.925

4.  Clinical assessment and train-of-four measurements in critically ill patients treated with recommended doses of cisatracurium or atracurium for neuromuscular blockade: a prospective descriptive study.

Authors:  Pierre Bouju; Jean-Marc Tadié; Nicolas Barbarot; Julien Letheulle; Fabrice Uhel; Pierre Fillatre; Guillaume Grillet; Angélique Goepp; Yves Le Tulzo; Arnaud Gacouin
Journal:  Ann Intensive Care       Date:  2017-01-19       Impact factor: 6.925

Review 5.  Approach to neuromuscular disorders in the intensive care unit.

Authors:  Kenneth C Gorson
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

6.  Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study.

Authors:  Nesrine Fraj; Khaoula Meddeb; Abdelbaki Azouzi; Sana Romdhani; Helmi Ben Saad; Mohamed Boussarsar
Journal:  Pan Afr Med J       Date:  2020-12-15

Review 7.  Consensus for the management of analgesia, sedation and delirium in adults with COVID-19-associated acute respiratory distress syndrome.

Authors:  Manuel Donato; Federico Carlos Carini; María Julia Meschini; Ignacio López Saubidet; Adela Goldberg; Marisol García Sarubio; Daniela Olmos; Rosa Reina
Journal:  Rev Bras Ter Intensiva       Date:  2021 Jan-Mar

8.  The Implementation of Protocol-Based Utilization of Neuromuscular Blocking Agent Using Clinical Variables in Acute Respiratory Distress Syndrome Patients.

Authors:  Sarah Hadique; Varun Badami; Michael Forte; Nicole Kovacic; Amna Umer; Amanda Shigle; Jordan Gardo; Rahul Sangani
Journal:  Crit Care Explor       Date:  2021-03-19

9.  Comparison between the Effects of Rocuronium, Vecuronium, and Cisatracurium Using Train-of-Four and Clinical Tests in Elderly Patients.

Authors:  Ozlem Sagir; Funda Yucesoy Noyan; Ahmet Koroglu; Muslum Cicek; Huseyin Ilksen Toprak
Journal:  Anesth Pain Med       Date:  2013-03-26

Review 10.  Neuromuscular blockade in patients with ARDS: a rapid practice guideline.

Authors:  Waleed Alhazzani; E Belley-Cote; M H Møller; D C Angus; L Papazian; Y M Arabi; G Citerio; B Connolly; L Denehy; A Fox-Robichaud; C L Hough; J H Laake; F R Machado; M Ostermann; T Piraino; S Sharif; W Szczeklik; P J Young; A Gouskos; K Kiedrowski; K E A Burns
Journal:  Intensive Care Med       Date:  2020-10-26       Impact factor: 17.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.